GlassScriptPhysician profile
Aleaha Ghant
NPI 1376299925
$3,487.54
in general payments reported to CMS, 2019-2025
27 companies · $856 in 2025
The $856 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $740 · 2023: $776 · 2024: $1,115 · 2025: $856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,747.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,747.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $845.41 | 2022-2025 | Breztri, Farxiga, Airsupra |
| Lilly USA, LLC | $452.54 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $363.09 | 2022-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $264.35 | 2023-2025 | |
| Novo Nordisk INC | $235.04 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Dexcom, INC. | $209.03 | 2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Amgen INC. | $138.25 | 2022-2025 | Otezla, Repatha |
| Antares Pharma, INC. | $134.16 | 2022-2025 | Xyosted, Nocdurna, Tlando |
| Phathom Pharmaceuticals, INC. | $121.60 | 2024 | Voquezna |
| Novartis Pharmaceuticals Corporation | $113.68 | 2022-2023 | |
| Glaxosmithkline, LLC. | $99.27 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Exact Sciences Corporation | $66.60 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.62 | 2022-2023 | |
| Boston Scientific Corporation | $57.47 | 2024-2025 | Watchman Flx |
| Biogen, INC. | $56.50 | 2025 | Zurzuvae |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $47.81 | 2023-2024 | Heplisav-B |
| Pfizer INC. | $47.21 | 2024-2025 | |
| Axsome Therapeutics, INC. | $27.56 | 2025 | Auvelity |
| Shield Therapeutics INC | $22.39 | 2022 | |
| Mylan Specialty L.P. | $20.71 | 2023 | Yupelri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.31 | 2022 | |
| Idorsia Pharmaceuticals US INC | $17.70 | 2022 | |
| Hologic Sales and Service, LLC | $15.86 | 2024 | Aptima |
| Astellas Pharma US INC | $14.83 | 2022 | |
| Organon LLC | $13.20 | 2022 | |
| Merck Sharp & Dohme LLC | $12.45 | 2022 | |
| Currax Pharmaceuticals LLC | $11.90 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aleaha Ghant listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.